Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats
Open Access
- 1 November 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (5) , 765-777
- https://doi.org/10.1038/sj.bjp.0707333
Abstract
Background and purpose: The ability of cannabinoids to suppress mechanical hypersensitivity (mechanical allodynia) induced by treatment with the chemotherapeutic agent vincristine was evaluated in rats. Sites of action were subsequently identified. Experimental approach: Mechanical hypersensitivity developed over the course of ten daily injections of vincristine relative to groups receiving saline at the same times. Effects of the CB1/CB2 receptor agonist WIN55,212‐2, the receptor‐inactive enantiomer WIN55,212‐3, the CB2‐selective agonist (R,S)‐AM1241, the opiate agonist morphine and vehicle on chemotherapy‐induced neuropathy were evaluated. WIN55,212‐2 was administered intrathecally (i.t.) or locally in the hindpaw to identify sites of action. Pharmacological specificity was established using competitive antagonists for CB1 (SR141716) or CB2 receptors (SR144528). Key results: Systemic administration of WIN55,212‐2, but not WIN55,212‐3, suppressed vincristine‐evoked mechanical allodynia. A leftward shift in the dose‐response curve was observed following WIN55,212‐2 relative to morphine treatment. The CB1 (SR141716) and CB2 (SR144528) antagonists blocked the anti‐allodynic effects of WIN55,212‐2. (R,S)‐AM1241 suppressed vincristine‐induced mechanical hypersensitivity through a CB2 mechanism. Both cannabinoid agonists suppressed vincristine‐induced mechanical hypersensitivity without inducing catalepsy. Spinal sites of action are implicated in cannabinoid modulation of chemotherapy‐induced neuropathy. WIN55,212‐2, but not WIN55,212‐3, administered i.t. suppressed vincristine‐evoked mechanical hypersensitivity at doses that were inactive following local hindpaw administration. Spinal coadministration of both the CB1 and CB2 antagonists blocked the anti‐allodynic effects of WIN55,212‐2. Conclusions and implications: Cannabinoids suppress the maintenance of vincristine‐induced mechanical allodynia through activation of CB1 and CB2 receptors. These anti‐allodynic effects are mediated, at least in part, at the level of the spinal cord. British Journal of Pharmacology (2007) 152, 765–777; doi:10.1038/sj.bjp.0707333; published online 18 June 2007Keywords
This publication has 71 references indexed in Scilit:
- Dysregulation of Cellular Calcium Homeostasis in Chemotherapy-Evoked Painful Peripheral NeuropathyAnesthesia & Analgesia, 2006
- A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in ratsPAIN®, 2005
- Identification and Functional Characterization of Brainstem Cannabinoid CB2ReceptorsScience, 2005
- Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in micePain, 2005
- The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic ratsNeuroscience Letters, 2004
- Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathyPAIN®, 2004
- Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEuropean Journal of Neuroscience, 2003
- Chemotherapy-evoked Painful Peripheral NeuropathyPain Medicine, 2001
- Two distinctive antinociceptive systems in rats with pathological painNeuroscience Letters, 2000
- Ethical guidelines for investigations of experimental pain in conscious animalsPAIN®, 1983